TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25495748

Group type: EXPERIMENTAL
Intervention: Integrated Risk Reduction Intervention (IRRI)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Psychiatric care with medical monitoring (Control)
Number of subjects: 122
Study: 23784896

Group type: EXPERIMENTAL
Intervention: Professional health coach
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Peer health coach
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Mentor health coach
Number of subjects: 44
Study: 21131132

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 28
Study: 20027436

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 7.5% hydrogen peroxide
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 10
Study: 17522018

Group type: EXPERIMENTAL
Intervention: First acquired memory with a reminder presented 5 min before the second training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second training given 5 min instead of 24 h after the first training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: First retrieval
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Absence of RIF effect
Number of subjects: 0
Study: 15249265

Group type: EXPERIMENTAL
Intervention: Visualization Group (standardized information supported by a tool for displaying two-dimensional pictures and informative leaflet)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control Group (standardized information and informative leaflet only)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Visualization Group
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 56
Study: 15259389

Group type: EXPERIMENTAL
Intervention: APOE epsilon4 allele
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Below average memory with APOE epsilon4 allele
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Below average memory without APOE epsilon4 allele
Number of subjects: 0

Group type: COMPARATOR
Intervention: Average or better memory with APOE epsilon4 allele
Number of subjects: 0
Study: 9871428

Group type: EXPERIMENTAL
Intervention: GI198745 (0.1 to 40 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 7658281

Group type: EXPERIMENTAL
Intervention: Amino acids (1.15 +/- 0.06 gm.kg‐1.day‐1) and glucose (6.05 +/- 1.58 gm.kg‐1.day‐1)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Glucose (6.48 +/- 1.30 gm.kg‐1.day‐1)
Number of subjects: 18
Study: 2696429

Group type: EXPERIMENTAL
Intervention: Povidone iodine (PVI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonmedicated soap (NMS)
Number of subjects: 0
Study: 325726

Group type: EXPERIMENTAL
Intervention: High doses of steroid drugs
Number of subjects: 36

Group type: COMPARATOR
Intervention: High doses of steroid drugs + 600 rads of radiotherapy to the graft
Number of subjects: 36
Study: 30759457

Group type: EXPERIMENTAL
Intervention: Nasal valve lift treatment using absorbable, polylactic acid, self‐retaining cone threads (Silhouette Soft)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nasal valve lift treatment using absorbable, polylactic acid, self‐retaining cone threads (Silhouette Soft) + turbinoplasty
Number of subjects: 60
Study: 27531752

Group type: EXPERIMENTAL
Intervention: Cal/BD foam
Number of subjects: 463

Group type: COMPARATOR
Intervention: Cal/BD gel
Number of subjects: 463
Study: 26283990

Group type: EXPERIMENTAL
Intervention: Metacognition-augmented cognitive remediation (CR)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Standard cognitive remediation (mybraintraining)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 90
Study: 25715721

Group type: EXPERIMENTAL
Intervention: Haas expander
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Hyrax expander
Number of subjects: 31
Study: 21497444

Group type: EXPERIMENTAL
Intervention: 40 mg cortisol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 19032566

Group type: EXPERIMENTAL
Intervention: Colloid boluses of 200 ml until stroke volume did not increase >or=10%
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Stroke volume measured beat to beat
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Stroke volume averaged over 10 heartbeats
Number of subjects: 20
Study: 17366758

Group type: EXPERIMENTAL
Intervention: 0.2% ZnCl2 toothpaste
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.66% AmF toothpaste
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both toothpastes
Number of subjects: 20
Study: 15016643

Group type: COMPARATOR
Intervention: CHOP‐21 (standard chemotherapy every 3 weeks)
Number of subjects: 689

Group type: COMPARATOR
Intervention: CHOEP‐21 (CHOP plus etoposide 100 mg/m2 days 1‐3)
Number of subjects: 689

Group type: EXPERIMENTAL
Intervention: CHOP‐14 (biweekly chemotherapy)
Number of subjects: 689

Group type: EXPERIMENTAL
Intervention: CHOEP‐14 (biweekly CHOP plus etoposide)
Number of subjects: 689
Study: 11757689

Group type: EXPERIMENTAL
Intervention: Triple eradication therapy (Clarithromycin 500 mg/d, Metronidazol 800 mg/d, Omeprazol 40 mg/d for 7 days)
Number of subjects: 2
Study: 9439537

Group type: EXPERIMENTAL
Intervention: T3 treatment
Number of subjects: 7
Study: 7907083

Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tolazoline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buflomedyl
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2890668

Group type: EXPERIMENTAL
Intervention: Bevantolol (HCl salt) after an overnight fast
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bevantolol (HCl salt) 15 minutes before breakfast
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bevantolol (HCl salt) 15 minutes after breakfast
Number of subjects: 12

Group type: COMPARATOR
Intervention: Bevantolol (HCl salt) after breakfast
Number of subjects: 12
Study: 29185480

Group type: EXPERIMENTAL
Intervention: JNJ‐39393406 (100 mg b.i.d.)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 27113448

Group type: EXPERIMENTAL
Intervention: Face to face tobacco cessation counseling session
Number of subjects: 39

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 39
Study: 24423155

Group type: EXPERIMENTAL
Intervention: 5 mg/day TTP488
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: 20 mg/day TTP488
Number of subjects: 399

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: TTP488 plasma concentrations (7.6-16.8 ng/mL)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: TTP488 plasma concentrations (46.8-167.0 ng/mL)
Number of subjects: 399
Study: 22188544

Group type: COMPARATOR
Intervention: Clopidogrel hydrogen sulfate (CHS) 600 mg loading dose followed by 75 mg/day
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Clopidogrel besylate (CB) 600 mg loading dose followed by 75 mg/day
Number of subjects: 96
Study: 20159820

Group type: EXPERIMENTAL
Intervention: 1-year aerobic exercise intervention of 225 min/wk (n = 160)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control group maintaining usual level of activity (n = 160)
Number of subjects: 320
Study: 17485382

Group type: EXPERIMENTAL
Intervention: Reduced intensity allogeneic stem cell transplantation (SCT) with lower intensity conditioning regimens.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermediate intensity, non‐myeloablative conditioning regimens.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Autologous transplant performed just prior to allografting.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peripheral blood cells and graft engineering to improve graft versus myeloma activity.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post transplant maintenance and targeted conditioning therapies such as bone seeking radioisotopes.
Number of subjects: 0
Study: 16130862

Group type: EXPERIMENTAL
Intervention: Micro Prime
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Gluma Desensitizer
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cervitec
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 11867179

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Propranolol in HVPG responders
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Propranolol in HVPG non-responders
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Propranolol in responders
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Propranolol in non-responders
Number of subjects: 44
Study: 10560446

Group type: EXPERIMENTAL
Intervention: Referral to specialists who enroll patients in clinical trials
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Belief in clinical trials increasing knowledge about treatment options
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Perception of randomised trials making a valuable scientific contribution
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Concerns about patient disadvantage in clinical trials
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Desire for optimum treatment for patients
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Desire to know about the trial
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Concerns about ethical considerations
Number of subjects: 85
Study: 7555486

Group type: EXPERIMENTAL
Intervention: High-carbohydrate low-fat (HCLF) diet
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Modified-fat (MF) diet
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 24
Study: 1552208

Group type: EXPERIMENTAL
Intervention: Natural human leukocyte interferon-alpha (IFN-alpha n3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3552010

Group type: EXPERIMENTAL
Intervention: Diazemuls (0.15 mg kg‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midazolam (0.07 mg kg‐1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (normal liver function)
Number of subjects: 0
Study: 31646475

Group type: EXPERIMENTAL
Intervention: Nebulized dexamethasone 8 mg 1 hour before surgery
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline nebulizer (control group)
Number of subjects: 80
Study: 29855840

Group type: EXPERIMENTAL
Intervention: MIHOW
Number of subjects: 188

Group type: COMPARATOR
Intervention: MEI
Number of subjects: 188
Study: 27385652

Group type: EXPERIMENTAL
Intervention: Exercise + diet management
Number of subjects: 36

Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 36
Study: 25943532

Group type: EXPERIMENTAL
Intervention: APC8015F
Number of subjects: 249

Group type: COMPARATOR
Intervention: sipuleucel-T
Number of subjects: 249
Study: 23958323

Group type: EXPERIMENTAL
Intervention: Porous silk fibroin scaffolds decorated with RGD sequences (SF-RGD) seeded with human mesenchymal stem cells (hMSC)
Number of subjects: 8
Study: 21614684

Group type: EXPERIMENTAL
Intervention: CAR27 device
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional stapling device
Number of subjects: 60
Study: 18496110

Group type: EXPERIMENTAL
Intervention: Computer-assisted learning (CAL)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Nonintervention group
Number of subjects: 23
Study: 16800343

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy using Cisplatin and Etoposide along with Wobe Mugos E
Number of subjects: 40

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy using Cisplatin and Etoposide
Number of subjects: 40
Study: 14615732

Group type: EXPERIMENTAL
Intervention: ReSoMaL
Number of subjects: 130

Group type: COMPARATOR
Intervention: WHO‐ORS
Number of subjects: 130
Study: 10925060

Group type: EXPERIMENTAL
Intervention: E/I ratio
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Valsalva
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: 30:15 ratio
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Sustained Handgrip
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Orthostatic BP
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Combination of two sympathetic tests
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Combination of all five tests
Number of subjects: 372
Study: 7799046

Group type: EXPERIMENTAL
Intervention: rhGM‐CSF
Number of subjects: 104
Study: 2129634

Group type: EXPERIMENTAL
Intervention: Low-lactose, low-fat feed (HN25)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional formula (SMA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hydrolysed soya and collagen feed (Prejomin)
Number of subjects: 60
Study: 6105118

Group type: EXPERIMENTAL
Intervention: 2 g daily sulphasalazine
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: 4 g daily sulphasalazine
Number of subjects: 170

Group type: COMPARATOR
Intervention: 1 g daily sulphasalazine
Number of subjects: 170
Study: 30008106

Group type: EXPERIMENTAL
Intervention: High-protein nutrient preload (50-g Parmesan cheese, one boiled egg, and 300-ml water)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Water (500-ml)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High-protein nutrient preload
Number of subjects: 16
Study: 28137487

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 29
Study: 26067942

Group type: EXPERIMENTAL
Intervention: Photon-Induced Photoacoustic Streaming (PIPS)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ultrasonic irrigation
Number of subjects: 24

Group type: COMPARATOR
Intervention: EndoActivator irrigation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Needle irrigation
Number of subjects: 24
Study: 23439274

Group type: EXPERIMENTAL
Intervention: Worksite vitality intervention (yoga, aerobic exercising, coaching, and fruit)
Number of subjects: 730

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: Worksite vitality intervention
Number of subjects: 730
Study: 21239636

Group type: EXPERIMENTAL
Intervention: Low-dose spironolactone (∼1 mg·kg(‐1)·day(‐1))
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Conventional dose spironolactone (∼30 mg·kg(‐1)·day(‐1))
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 19892627

Group type: EXPERIMENTAL
Intervention: Xenoderm
Number of subjects: 78

Group type: COMPARATOR
Intervention: 1% silver sulfadiazine (SSD)
Number of subjects: 78
Study: 16517517

Group type: EXPERIMENTAL
Intervention: Task-switching paradigm in children with SLI
Number of subjects: 13

Group type: COMPARATOR
Intervention: Task-switching paradigm in children without SLI (control group)
Number of subjects: 13
Study: 14688530

Group type: EXPERIMENTAL
Intervention: Sirolimus monotherapy (n=11)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Calcineurin inhibitors (n=12)
Number of subjects: 23
Study: 10699769

Group type: EXPERIMENTAL
Intervention: Disposable forceps
Number of subjects: 200

Group type: COMPARATOR
Intervention: Reusable forceps
Number of subjects: 200
Study: 9315493

Group type: EXPERIMENTAL
Intervention: Yohimbine hydrochloride (30 mg/day, two 5 mg tablets three times daily for eight weeks)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Yohimbine hydrochloride
Number of subjects: 86
Study: 7964947

Group type: EXPERIMENTAL
Intervention: rIFN‐gamma at a dose of 4 x 10(6) U subcutaneously per day for 6 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: rIFN‐gamma treatment
Number of subjects: 100
Study: 3301260

Group type: EXPERIMENTAL
Intervention: Five bio‐ or semisynthetic human insulins (specific preparations not detailed) tested at equal dosages.
Number of subjects: 0
Study: 31828805

Group type: EXPERIMENTAL
Intervention: Expanded breakfast service (Second Chance Breakfast)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Traditional before school cafeteria SBP service
Number of subjects: 12

Group type: COMPARATOR
Intervention: Travel method (car, bike, walking)
Number of subjects: 12
Study: 29562318

Group type: EXPERIMENTAL
Intervention: Treatment intervention
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 97
Study: 26004041

Group type: EXPERIMENTAL
Intervention: Flexibility training (static stretching) for 4 weeks, 4 days/week
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no flexibility training)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Flexibility training (static stretching)
Number of subjects: 23
Study: 25625966

Group type: EXPERIMENTAL
Intervention: Concussion (n=40)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: mTBI (n=41)
Number of subjects: 122

Group type: COMPARATOR
Intervention: No diagnosis (control condition; n=41)
Number of subjects: 122
Study: 23700578

Group type: EXPERIMENTAL
Intervention: Group 3: veneer: 4% hydrofluoric acid (HF) + core: 30 µm aluminum trioxide particles coated with silica + core + veneer: silane
Number of subjects: 40

Group type: COMPARATOR
Intervention: Group 1: veneer: 4% hydrofluoric acid (HF) + core: aluminum trioxide (50‐µm Al2O3) + core + veneer: silane
Number of subjects: 40

Group type: COMPARATOR
Intervention: Group 2: core: Al2O3 (50 µm) + veneer: HF + core + veneer: silane
Number of subjects: 40

Group type: COMPARATOR
Intervention: Group 4: core: 30 µm SiO2 + veneer: HF + core + veneer: silane
Number of subjects: 40
Study: 20962913

Group type: EXPERIMENTAL
Intervention: Protein plus carbohydrate (PRO) beverage (40 g carbohydrate, 20 g whey protein)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Carbohydrate (CHO) beverage (60 g)
Number of subjects: 12
Study: 18641111

Group type: EXPERIMENTAL
Intervention: Bilevel positive airway pressure (PAP)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Comparison of Bilevel PAP vs CPAP
Number of subjects: 24
Study: 16858161

Group type: EXPERIMENTAL
Intervention: Flutamide 250 mg/d
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Flutamide
Number of subjects: 60

Group type: COMPARATOR
Intervention: Flutamide and Placebo
Number of subjects: 60
Study: 12873996

Group type: EXPERIMENTAL
Intervention: Serum IGF-I levels
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Serum IGFBP-3 levels
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Serum IGF-I levels in cases
Number of subjects: 121

Group type: COMPARATOR
Intervention: Serum IGF-I levels in controls
Number of subjects: 121
Study: 10870746

Group type: EXPERIMENTAL
Intervention: Capsaicinoids
Number of subjects: 0
Study: 8796404

Group type: EXPERIMENTAL
Intervention: Continuous cardiac output measurement by the Fick principle
Number of subjects: 25

Group type: COMPARATOR
Intervention: Thermodilution cardiac output measurement
Number of subjects: 25
Study: 1735847

Group type: EXPERIMENTAL
Intervention: Surfactant (Exosurf Neonatal)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Air (placebo)
Number of subjects: 30
Study: 6143975

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 2 X 10(6) units IFN‐beta for 10 consecutive days
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo injections for 10 consecutive days
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: IFN‐beta treatment for non-responders after 3 months
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: IFN‐beta treatment
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Intramuscular injections of IFN‐beta
Number of subjects: 22
Study: 30681166

Group type: EXPERIMENTAL
Intervention: 308-nm excimer laser (EL)
Number of subjects: 21

Group type: COMPARATOR
Intervention: 311-nm Titanium:Sapphire laser (TSL)
Number of subjects: 21
Study: 29059367

Group type: EXPERIMENTAL
Intervention: Metabolism-informed care (MIC)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Guideline based care (GBC)
Number of subjects: 81
Study: 26830098

Group type: EXPERIMENTAL
Intervention: Supervised Exercise Training (SET)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Non-Supervised Exercise Training (nSET)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy Controls
Number of subjects: 40
Study: 24274379

Group type: EXPERIMENTAL
Intervention: Enteral immunonutrition (IN) with omega‐3 fatty acids, glutamine, and arginine
Number of subjects: 71

Group type: COMPARATOR
Intervention: Standard formula (Control)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Enteral immunonutrition (IN)
Number of subjects: 71
Study: 22227851

Group type: COMPARATOR
Intervention: 1,000 mL of milk
Number of subjects: 24

Group type: COMPARATOR
Intervention: 500 mL of milk
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 19606529

Group type: EXPERIMENTAL
Intervention: Ziprasidone (80-160 mg/day)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Clozapine (250-600 mg/day)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 147

Group type: COMPARATOR
Intervention: Clozapine
Number of subjects: 147
Study: 17891598

Group type: EXPERIMENTAL
Intervention: GnRH agonist
Number of subjects: 500

Group type: COMPARATOR
Intervention: No GnRH agonist
Number of subjects: 500
Study: 14713745

Group type: EXPERIMENTAL
Intervention: Various agents including dietary supplements, finasteride, and cyclooxygenase-2 inhibitors
Number of subjects: 11
Study: 12665916

Group type: EXPERIMENTAL
Intervention: Famciclovir
Number of subjects: 89

Group type: COMPARATOR
Intervention: Interferon (IFN) alpha
Number of subjects: 89

Group type: COMPARATOR
Intervention: Lamivudine
Number of subjects: 89
Study: 9655014

Group type: EXPERIMENTAL
Intervention: Display duration of 20 ms
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Display duration of 1000 ms
Number of subjects: 100
Study: 8074071

Group type: EXPERIMENTAL
Intervention: 15 mg cholecalciferol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 5 mg cholecalciferol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2.5 mg cholecalciferol every 3 months
Number of subjects: 60